Emergen Research’s latest market research report, titled Global Viral and Non-Viral Vector Manufacturing Market, provides estimated market size and shares, latest industry trends, global market growth rates, key drivers and opportunities, constraints, product segmentation, and major market players. Cost structure, market size, competitive landscape, product portfolio and specifications, and company profiles.
This report is a fair prototype of the Viral and Non-Viral Vector Manufacturing-industry containing an in-depth study of the global Viral and Non-Viral Vector Manufacturing market. This report serves as a valuable source of data and information related to this industry. It covers various industry aspects with a particular focus on market scope and application areas. The report identifies the fundamental business strategies adopted by industry experts and offers an insightful study on the value chains and distribution channels of the global market. The report authors have also analyzed current industry trends, growth potential, current overview, and market limitations.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4236
The Viral and Non-Viral Vector Manufacturing market is expected to grow from an estimated USD 2.8 billion in 2024 to USD 13.4 billion in 2033 at a CAGR of 19.00%.
The global Viral and Non-Viral Vector Manufacturing market size is expected to grow from 11.5 billion by the end of 2024 to 21.1 billion by 2033, registering a revenue CAGR of 7.00% during the forecast period. Hereditary diseases affect about one in ten individuals; effective treatment strategies are constantly in great demand. This alarming trend drives researchers, clinicians, and pharmaceutical companies to look to gene-based medicines as potential remedies.
As such, increased focus is on building and generating pathways of development capable of securely and successfully supplying repaired genes. This need for targeted treatments improves the market conditions and drives manufacturers to develop and optimize their vector production methods. Genetic diseases are conditions either totally or partially caused by a variation from the usual DNA sequence. By delivering therapeutic genes to target cells, viral vectors either replace or augment the faulty genes generating genetic diseases. Ex vivo gene therapy uses non-viral vectors, in which cells are genetically altered outside the body and subsequently reinfused into the patient.
According to the International Diabetes Federation, a Belgium-based diabetes federation, the prevalence of diabetes had risen to 10.5% worldwide in June 2022; over half, (44.7%) of people were still undiagnosed, and roughly 783 million adults, or one in every eight people, expected to have diabetes by 2045. Consequently, the rising frequency of genetic diseases fuels the expansion of the market for both non-viral and viral vectors.
Furthermore, the increasing number of clinical studies is likely to drive the expansion of the markets for both viral and non-viral vectors. Clinical trials are research designed to evaluate the safety, efficacy, and probable adverse effects of a medicine, therapy, or medical intervention, including human volunteers. Both viral and non-viral vector production are indispensable in supporting gene therapy clinical trials by way of the necessary tools for delivering therapeutic genes to patients and assuring the safety, quality, and scalability of these vectors throughout the trial stages.
According to the US-based web-based resource ClinicalTrials.gov, maintained under the US National Library of Medicine, information about clinical trials in the year 2022 indicated 56,561 of the 437,515 registered clinical studies completed in December 2023. In December 2023, registration and completion showed growing tendencies. Specifically, 61,504 completed registered clinical studies out of 476,526 earlier. Consequently, the increasing number of clinical studies is fuelling the expansion of the markets for both viral and non-viral vectors.
Key market aspects studied in the report:
Market Scope: The report explains the scope of various commercial possibilities in the global Viral and Non-Viral Vector Manufacturing market over the upcoming years. The estimated revenue build-up over the forecast years has been included in the report. The report analyzes the key market segments and sub-segments and provides deep insights into the market to assist readers with the formulation of lucrative strategies for business expansion.
Competitive Outlook: The leading companies operating in the Viral and Non-Viral Vector Manufacturing market have been enumerated in this report. This section of the report lays emphasis on the geographical reach and production facilities of these companies. To get ahead of their rivals, the leading players are focusing more on offering products at competitive prices, according to our analysts.
Report Objective: The primary objective of this report is to provide the manufacturers, distributors, suppliers, and buyers engaged in this sector with access to a deeper and improved understanding of the global Viral and Non-Viral Vector Manufacturing market.
Market Segmentation:
The report bifurcates the Viral and Non-Viral Vector Manufacturing market on the basis of different product types, applications, end-user industries, and key regions of the world where the market has already established its presence. The report accurately offers insights into the supply-demand ratio and production and consumption volume of each segment.
The presence of global and regional players such as Boehringer Ingelheim, Catalent, Inc., FUJIFILM Holdings Corporation, Danaher Corporation, Genscript Biotech Corporation and others characterises market competition in the Viral and Non-Viral Vector Manufacturing industry. The Viral and Non-Viral Vector Manufacturing market is notably expanding in response to the increasing need for better biopharmaceuticals and gene therapies.
This industry is defined by the development and manufacture of viral vectors required for delivering gene therapies, vaccines, and other biologics. Several large corporations define the competitive environment by means of manufacturing process development, increase of production capacity, and strategic alliance creation, thereby striving for market dominance. Legal restrictions, technical developments, and the increasing frequency of genetic diseases affect the dynamics of the industry and, hence, increase the competitiveness among top corporations.
For instance, in Dec 2024, Leading plasmid DNA-based immunotherapy Genetic immunity (GI) discovered a crucial link with the worldwide gene dissemination solution Vector Builder. Based on the encouraging clinical outcomes from earlier trials, the partnership intends to put GI’s creative plasmid DNA HIV vaccine into Phase 3 testing.
Some of the key companies in the global Viral and Non-Viral Vector Manufacturing Market include:
- Boehringer Ingelheim
- Catalent, Inc.
- FUJIFILM Holdings Corporation
- Â Danaher Corporation
- Genscript Biotech Corporation
- Lonza Group AG
- Merck KGaA Inc.
- Â Oxford Biomedica plc
- Thermo Fisher Scientific Inc.
- Advanced BioScience Laboratories
- AGC Biologics
- Aldevron
Target Audience of the Global Viral and Non-Viral Vector Manufacturing Market Report:
- Key Market Players
- Investors
- Venture capitalists
- Small- and medium-sized and large enterprises
- Third-party knowledge providers
- Value-Added Resellers (VARs)
- Global market producers, distributors, traders, and suppliers
- Research organizations, consulting companies, and various alliances interested in this sector
- Government bodies, independent regulatory authorities, and policymakers
By Vector Type Outlook (Revenue, USD Billion; 2020-2033)Â
- Viral Vector
- Adenoviral Vector
- Retroviral Vector
- Adeno-Associated Viral Vector
- Lentiviral Vector
- Vaccinia Viral Vector
- Other Viral Vector
- Non-Viral Vector
- Plasmid DNA
- Lipid-Based Non-Viral Vector
- Polymer-Based Non-Viral Vector
- Other Non-Viral Vectors (Peptide-Based and Hybrid/Combination)
By Diseases Outlook (Revenue, USD Billion; 2020-2033)Â
- Cancer
- Genetic Disease
- Infectious Disease
- Cardiovascular Disease
- Other Diseases
By Application Outlook (Revenue, USD Billion; 2020-2033)Â
- Gene Therapy
- Viral Vector
- Non-Viral Vector
- Vaccinology
- Viral Vector
- Non-Viral Vector
- Cell Therapy
- Viral Vector
- Non-Viral Vector
- Other Applications
- Viral Vector
- Non-Viral Vector
By Regional Outlook (Revenue, USD Billion; 2020-2033)Â
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
Browse Full Report Description + Research Methodology + Table of Content + Infographics@ https://www.emergenresearch.com/industry-report/viral-and-non-viral-vector-manufacturing-market
Competitive Terrain:
The global Viral and Non-Viral Vector Manufacturing industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.
Advancements In Vector Technology
Technological developments significantly influence the Viral & Non-Viral Vector Manufacturing Market. Innovations in better plasmid DNA design, improved viral packing methods, and fresh non-viral delivery techniques are turning the efficacy and safety of gene delivery around. The development of next-generation vectors, including modified viral vectors and self-amplifying RNA, presents reduced immunogenicity and greater transfection rates.
As they open opportunities, successful gene therapies made feasible by these advances attract both investors and pharmaceutical companies. Therefore, better vector technologies are expected to promote market development as they provide more efficient solutions for gene delivery challenges.
For instance, NecstGen, a Netherlands-based CDMO providing all-encompassing support for all developers in the field of Cell and Gene Therapy, worked with ProteoNic BioSciences, a Netherlands-based technology provider for the manufacturing of complex therapeutic proteins, to launch ProteoNick’s 2G UNic premium vector technology in September 2023. By means of the successful application of this technology, lentiviral (LV) vectors have been developed, enhancing functional viral particle titters and immediately improving process efficiency, thus raising the cost-effectiveness and availability of treatments.
Key reasons to buy the Global Viral and Non-Viral Vector Manufacturing Market report:
- The latest report comprehensively studies the global Viral and Non-Viral Vector Manufacturing market size and provides useful inference on numerous aspects of the market, such as the current business trends, market share, product offerings, and product share.
- The report offers an insightful analysis of the regional outlook of the market.
- It offers a detailed account of the end-use applications of the products & services offered by this industry.
- The report holistically covers the latest developments taking place in this industry. Therefore, it lists the most effective business strategies implemented by the market rivals for ideal business expansion.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4236
Thank you for reading our report. For further details or to inquire about customization, please let us know and we will offer you the report as per your needs.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com